Tyra Biosciences, Inc.

Equities

TYRA

US90240B1061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
16.22 ^USD	+2.98%		-6.35%	+17.11%

13/05	Oppenheimer Adjusts Tyra Biosciences Price Target to $28 From $25, Maintains Outperform Rating	MT
09/05	Tyra Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tyra Biosciences, Inc. Expects to Submit an Investigational New Drug Application to the U.S. Food and Drug Administration to Enable a Phase 2 Study of TYRA-300 in Pediatric Achondroplasia in 2024

March 23, 2023 at 01:36 am IST

Tyra Biosciences, Inc. expected to submit an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to enable a Phase 2 study of TYRA-300 in pediatric achondroplasia in 2024.

Latest news about Tyra Biosciences, Inc.

Oppenheimer Adjusts Tyra Biosciences Price Target to $28 From $25, Maintains Outperform Rating	13/05	MT
Tyra Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Tyra Biosciences, Inc. Announces Board Changes	08/05	CI
HC Wainwright Adjusts Tyra Biosciences Price Target to $23 From $19, Maintains Buy Rating	20/03	MT
Tyra Biosciences Q4 Net Loss Widens	20/03	MT
Tyra Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03	CI
Transcript : Tyra Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:00 AM	14/03
Tyra Biosciences, Inc. announced that it has received $200.006021 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC	06/02	CI
Wedbush Lifts Tyra Biosciences' PT to $28 From $27, Tweaks Financing Assumptions; Keeps Outperform Rating	05/02	MT
Sector Update: Health Care Stocks Advance Late Afternoon	03/02	MT
Sector Update: Health Care	03/02	MT
Tyra Biosciences Launches $200 Million Private Placement; Shares Rise	03/02	MT
Top Midday Gainers	03/02	MT
Tyra Biosciences Launches $200 Million Private Placement; Shares Rise	02/02	MT
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for Potential Achondroplasia Treatment	02/02	MT
Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy	02/02	DJ
Tyra Biosciences, Inc. Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia	02/02	CI
Tyra Biosciences, Inc. announced that it expects to receive $200.006021 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC	01/02	CI
Tyra Biosciences, Inc. Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300	22/12	CI
Tyra Biosciences Doses 1st Patient in Phase 1 Liver Cancer Treatment Trial	23/12	MT
HC Wainwright Adjusts Price Target on Tyra Biosciences to $19 From $20, Maintains Buy Rating	08/11	MT
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
HC Wainwright Adjusts Price Target on Tyra Biosciences to $20 From $17, Keeps Buy Rating	11/23/11	MT
Tyra Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI

Chart Tyra Biosciences, Inc.

Duration

Period

More charts

Company Profile

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.22 USD

Average target price

24.5 USD

Spread / Average Target

+51.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TYRA BIOSCIENCES, INC.	+17.11%	85Cr
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research